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Abstract
Introduction: In the current study, we evaluated the accuracy of sentinel node mapping in thyroid cancer patients using both radiotracer and blue dye.
Material and methods: 30 patients with a diagnosis of papillary thyroid carcinoma (PTC) were included in the study; 2–3 hours before 
surgery, 0.5 mCi 99m-Tc-Antimony Sulfide Colloid was injected intra-tumourally. 15 minutes post-injection, lymphoscintigraphy images 
of the neck were obtained. Immediately after anaesthesia induction, 0.5 mL patent blue V was also injected in the same fashion. Sentinel 
lymph nodes were detected intraoperatively using gamma probe and blue dye. Total thyroidectomy was performed for all patients with 
dissection of central neck lymph nodes as well as sampling of the lateral neck lymph nodes. 
Results: At least one sentinel node could be identified during surgery in 19 patients (63.3%). The median number of sentinel nodes per patient 
was 1. Sentinel nodes in 12 patients were pathologically involved. No false negative case was noted. Upstaging occurred in six patients (20%). 
Conclusions: Sentinel node mapping in papillary thyroid carcinoma is a feasible technique with high accuracy for the detection of lymph 
node involvement. This technique can guide surgeons to perform central lymph node dissection only in patients with pathologically 
involved sentinel nodes. Although SLN detection in the lateral neck lymph nodes increases the extension of lymphadenectomy, SLN 
mapping can result in upstaging in older patients (> 45 years of age) or treatment plan change in younger patients (< 45 years of age) by 
the detection of lateral lymph node involvement. (Endokrynol Pol 2014; 65 (4): 281–286)
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Streszczenie
Wstęp: W badaniu oceniono dokładność mapowania węzłów wartowniczych u chorych na raka tarczycy w przypadku jednoczesnego 
zastosowania radioznacznika i niebieskiego barwnika.
Materiał i metody: Do badania włączono 30 chorych z rozpoznaniem raka brodawkowego tarczycy (PTC, papillary thyroid carcinoma). 
Dwie do trzech godzin przed zabiegiem do guza wstrzykiwano koloid siarczanu antymonu znakowany 99m-Tc (0,5 mCi). Po upływie 
15 minut od wstrzyknięcia radioznacznika wykonywano badanie limfoscyntygraficzne szyi. Bezpośrednio po znieczuleniu w ten sam 
sposób wstrzykiwano 0,5 ml błękitu patentowego V. Węzły wartownicze wykrywano śródoperacyjnie, używając sondy promieniowania 
gamma i błękitnego barwnika. U wszystkich pacjentów wykonano totalną tyroidektomię z wycięciem węzłów chłonnych szyjnych środ-
kowego przedziału oraz pobraniem wycinków węzłów szyjnych bocznych.
Wyniki: U 19 chorych (63,3%) udało się zidentyfikować w trakcie zabiegu co najmniej jeden węzeł wartowniczy. Mediana liczby węzłów 
wartowniczych na pacjenta wynosiła 1. U 12 chorych w węzłach wartowniczych wykryto zmiany patologiczne. Nie stwierdzono ani 
jednego przypadku uzyskania fałszywie ujemnego wyniku. U 6 (20%) chorych zmieniono stopień zaawansowania nowotworu na wyższy.
Wnioski: Mapowanie węzłów wartowniczych w raku brodawkowatym tarczycy jest dostępną metodą cechującą się dużą dokładno-
ścią w wykrywaniu zajętych węzłów chłonnych. Ta metoda może stanowić wskazówkę dla chirurgów, aby usuwać węzły chłonne 
szyjne środkowego przedziału tylko u pacjentów ze zmianami w węzłach wartowniczych. Mimo, że wykrycie węzłów wartowniczych 
w obrębie węzłów szyjnych bocznych zwiększa zakres limfadenektomii, mapowanie węzłów wartowniczych może spowodować zmianę 
oceny stopnia zaawansowanie nowotworu u starszych pacjentów (> 45 lat) lub zmianę planu leczenia u młodszych pacjentów (< 45 lat) 
w związku z wykryciem zmian w węzłach bocznych szyi. (Endokrynol Pol 2014; 65 (4): 281–286)
Słowa kluczowe: węzeł wartowniczy; rak tarczycy; limfoscyntygrafia; niebieski barwnik; radioznacznik
Introduction
Sentinel node mapping is an important technique in the 
lymph node staging of solid tumours. This technique 
relies on the orderly progression of the metastases in 
the lymphatic system. Lymphatic drainage of solid 
tumours usually drains to single or multiple lymph 
nodes (which are called sentinel nodes [SN]) and then 
282
PR
A
C
E 
O
RY
G
IN
A
LN
E
Sentinel node mapping in thyroid cancer   Mahdi Assadi et al.
spreads to other regional lymph nodes. The main aim 
of sentinel node mapping is to identify regional lymph 
node metastasis without performing regional lymph 
node dissection [1, 2].
Sentinel node mapping is currently considered as 
the standard of care in lymph node staging of breast 
cancer and melanoma [3]. It is also considered very 
promising in urological [4, 5], gynaecological [6], gas-
trointestinal [7], and many other solid tumours. 
Papillary thyroid carcinoma is the most common 
type of differentiated thyroid cancer with a high rate 
of regional lymph node metastasis [8, 9]. Regional 
lymph node dissection is recommended for patients 
with macroscopic lymph node metastases in order to 
decrease regional recurrence [10]. On the other hand, 
prophylactic central and/or lateral lymph node dissec-
tion for clinically node negative patients is controversial. 
Central lymph node dissection can cause considerable 
morbidity such as permanent damage to parathyroid 
glands and recurrent laryngeal nerves [11–13]. Sentinel 
node mapping may be especially helpful in clinically 
node negative thyroid cancer patients to avoid unneces-
sary lymph node dissection in sentinel node negative 
patients.
Since 1998, several groups have reported their ex-
perience in sentinel node mapping of thyroid cancer 
with various detection and false negative rates [14–16]. 
In the current study, we evaluated the accuracy of sen-
tinel node mapping for regional lymph node staging of 
patients with clinically node negative papillary thyroid 
carcinoma (PTC) by the combined radiotracer and blue 
dye techniques. 
Material and methods
In this prospective study, from April 2010 to December 
2012, 34 consecutive patients with evidence of PTC on 
fine needle aspiration (FNA) were included in the study. 
On clinical examination, all patients were clinically node 
negative. All patients also underwent thyroid and neck 
ultrasonography and no patient had evidence of lymph 
node enlargement. The study was approved by the local 
ethical committee under approval number 88830. All 
patients gave informed written consent before enter-
ing the study. 
Two to three hours before surgery, all patients were 
sent to the nuclear medicine department for radi-
otracer injection. For each patient, 0.5 mCi (18.5 MBq)/ 
/0.2 mL Tc-99m Antimony Sulfide Colloid was injected 
intra-tumourally. Fifteen minutes post-injection, lym-
phoscintigraphy imaging of the neck was performed 
in anterior-posterior and lateral views (5 min/image, 
128 × 128 matrix, low energy high resolution collimator 
and Tc-99m photopeak). The body contours of the pa-
tients were imaged as described by Momennezhad et al. 
[17, 18]. The lymphoscintigraphy images were interpreted 
by two nuclear medicine specialists independently, and 
the discordant readings were resolved by consensus. 
All patients also received 0.5 mL patent blue V intra-
tumourally immediately after anaesthesia induction. 
Total thyroidectomy was performed for all patients 
with dissection of central neck lymph nodes as well as 
sampling of the lateral neck lymph nodes. 
The sentinel nodes were harvested during surgery by 
a gamma probe (EUROPROBE, France). All hot and/or 
blue nodes were considered as sentinel nodes and were 
sent separately to the pathologist. Hot nodes were de-
fined as any node with an ex vivo count five times higher 
than the neck background which was measured on the 
carotid vessels. Following removal of the sentinel nodes, 
central lymph node (level VI) dissection was done for 
all patients. In addition, compartment based lymph 
node dissection was done for those patients found 
to have SLN. Finally, lymph node sampling from the 
other lymph node stations (at least three nodes from 
the lateral neck nodes) was done for all patients.
The pathological results of the SLN were compared 
to the other excised non-SLN to determine the false 
negative rate.
Results
Thirty four patients were initially included in the study. 
The radiotracer labelling was defective in four patients, 
and so they were excluded from the final report [19]. 
Thirty patients were available for final analyses, with 
an age range of 18–55 (mean age 34 ± 8 years) and F/M 
equal to 22/8. Mean size of the tumour was 1.5 ± 0.4 cm.
On the pre-operative lymphoscintigraphy, SLN 
could be identified in 20 patients (66.6%). Figures 1 
and 2 show the lymphoscintigraphy images of two of 
our patients.
Intra-operatively, SLN could be harvested in 19 pa-
tients (detection rate of 63.3% [95% CI: 45.1–78.4%]). 
Overall, 27 SLN were harvested (range 1–3, median 
1 per patient). The lymphoscintigraphy images of 
a patient with visualised SLN but surgical detection 
failure were re-evaluated; the reason for the inability 
to harvest SLN in this patient was misinterpretation 
of a hot spot in the injection track line as a SLN by the 
nuclear physicians. 
Eight (72%) of the SLN detection failures occurred 
in the first half of the study (the first 15 recruited pa-
tients). There were only three SLN detection failures 
in the remaining 15 patients who were recruited in the 
second half of the study. 
All harvested SLNs were hot (radiotracer detection 
rate of 63.3%). Blue SLNs were identified in nine pa-
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Figure 1. Anterior (upper row, left), and posterior (upper row, right) lymphoscintigraphy images of a patient with thyroid cancer. 
Note sentinel lymph node distal to the injection site which is apparent on the anterior view only (arrow). Bottom row images are the 
corresponding scatterograms of the lymphoscintigraphy images which show the contour of the neck
Rycina 1. Obraz limfoscyntygrafii w projekcji przedniej (górny rząd, po lewej) i tylnej (górny rząd, po prawej) u chorego na raka 
tarczycy. Należy zwrócić uwagę na węzeł chłonny wartowniczy oddalony od miejsca wstrzyknięcia, widoczny tylko w projekcji przedniej 
(strzałka). Obrazy w dolnym rzędzie to odpowiednie skaterogramy obrazów limfoscyntyfrafii, na których widać zarys szyi
Figure 2. Anterior (left) lymphoscintigraphy image of a patient with thyroid cancer. Note the SLN in the lateral region of the neck 
(arrow). The image on the right is the corresponding scatterogram
Rycina 2. Obraz limfoscyntygrafii w projekcji przedniej (po lewej) u chorego na raka tarczycy. Należy zwrócić uwagę na węzeł 
wartowniczy znajdujący się w bocznej części szyi (strzałka). Obraz po prawej stronie to odpowiedni skaterogram
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Figure 3. Location distribution of the harvested sentinel lymph 
nodes during surgery
Rycina 3. Rozkład lokalizacji węzłów wartowniczych pobranych 
w trakcie zabiegu chirurgicznego
tients (blue dye detection rate of 30%). The location of 
the harvested SLNs is shown in Figure 3.
Sentinel lymph nodes were pathologically involved 
in 12 patients (63.2% of patients with identified SLN). In 
two patients, the SLN were the only involved nodes. Six 
patients with SLN detection failure had pathologically 
involved lymph nodes (54% of patients with SLN detec-
tion failure). No false negative case was noted (100% 
[95% CI: 74–100%]sensitivity). Upstaging occurred in six 
patients (20%), details of whom can be found in Table I. 
In a 23-year-old patient, a lateral sentinel lymph node 
(station V) was pathologically involved and the stag-
ing did not change; however, due to increase of the N 
stage from N0 to N1b, radioiodine therapy (150 mCi) 
was administered to the patient.
No adverse event related to sentinel node mapping 
was reported in our study.
Discussion
In the current study, we evaluated the accuracy of SLN 
mapping in the staging of papillary thyroid cancer us-
ing combined radiotracer and blue dye techniques. The 
SLN detection rate was 63.3%, which is fairly acceptable 
for clinical use. However, recent systematic reviews 
showed a pooled sentinel node detection rate of more 
than 90% [14, 15]. The reason of this discrepancy is 
most likely due to the injection technique of our study. 
We used an intra-tumoural injection technique which 
theoretically could decrease the sentinel node detection 
rate due to poor lymphatic drainage from the tumour 
parenchyma compared to the peri-tumoural area [20, 
21]. Several groups have also used intra-tumoural injec-
tion of the mapping material for thyroid cancer patients 
with the same results as ours (about 60% SLN detection 
rate) [22–24], which corroborate our results. Another 
possible reason for the low detection rate in our study 
compared to the previous studies is the learning curve 
effect. Learning curve effect has been shown to be an 
important parameter in the SLN mapping success [6, 25, 
26]. In our study, the majority of SLN detection failure 
(72%) occurred among the first 15 recruited patients, 
which shows a possible learning curve effect. 
Another important finding of our study was con-
siderably lower sentinel node detection rate by blue 
dye compared to radiotracer method (30% vs. 63.3%). 
All of the harvested sentinel nodes were hot and blue 
only sentinel nodes were not identified in our study. In 
other words, blue dye technique was not useful in our 
patients. A lower detection rate using the blue dye tech-
nique compared to the radiotracer has been reported 
in other malignancies (including thyroid cancer) too 
[15, 27]. Considering the adverse reactions associated 
with blue dyes [28] and possible staining of parathyroid 
glands by blue dye [22, 29], our results suggest that 
a radiotracer only technique would be sufficient for 
sentinel node mapping in thyroid cancer patients.
We had an excellent accuracy for lymph node stag-
ing in our study (no false negative result). This means 
that pathological examination of the harvested sentinel 
nodes could predict central and/or lateral lymph node 
stations involvement. Overall, other studies also cor-
Table I. Characteristics of the upstaged patients by sentinel node mapping
Tabela I. Charakterystyka pacjentów, u których zmieniono stopień zaawansowania nowotworu na wyższy po mapowaniu 
węzłów wartowniczych
Patient 
number
Age/gender Tumour  
size [cm]
Number of harvested  
SLNs/location (level)
Location (level)  
of the involved SLNs
Location of the pathologically  
involved non-SLN
Stage shift
1 49/M 1.8 2/IV,VI IV IV I to IVa
2 48/F 4.3 1/IV IV IV III to IVa
3 51/F 1.5 1/IV IV IV I to IVa
4 55/M 3.5 1/V V V II to IVa
5 50/F 2.2 1/IV IV IV II to IVa
6 48/F 2.5 2/V,VI V Only SLN was involved II to IVa
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roborated our results. Recent meta-analysis showed 
a low pooled false negative rate of 7.7% [14]. Several 
other studies also reported a 0% false negative rate 
which also corroborates our results [22, 30, 31].
The location of SLN is another important aspect 
of our study. 40% of the harvested SLNs in our study 
were located in lateral compartments (levels II, III, IV) 
and SLNs in the lateral compartments were the only 
SLNs in seven patients (23% of the patients). These 
results were in accordance with the previous studies 
too. Balasubramanian et al. reported that in 15 studies 
on thyroid cancer SLN mapping, 22.5% of the harvested 
SLNs were in the lateral locations, and 14.8% of patients 
had only lateral SLNs [14]. 
Lymphadenectomy outside the central neck com-
partment is not routinely performed in our centre and 
many centres around the world. This shows that SLN 
mapping could help to identify cases that require more 
extensive lymph node dissection and paradoxically 
could result in more extensive surgeries. To explore 
this issue more extensively, we also evaluated the pos-
sibility of upstaging by SLN mapping compared to 
the traditional total thyroidectomy and central lymph 
node dissection. As mentioned above, only central 
lymph node compartments are routinely removed in 
our centre for thyroid cancer patients and lymph node 
involvement in the lateral compartments would remain 
undetected. This may pose a potential staging problem 
in patients over 45 years of age, as lateral lymph node in-
volvement in these patients can increase the stage. Our 
study showed that in six cases (all > 45 year old), SLN 
mapping upstaged the patients. This is an important 
finding demonstrating that SLN mapping in thyroid 
cancer can be much more useful in elderly patients [32]. 
We also had a young patient (23 years old) in whom the 
lateral lymph node involvement was discovered only by 
SLN mapping. This finding led to a treatment change 
using high dose radioiodine therapy and stricter TSH 
suppression despite no change in the staging. 
Conclusion
SLN mapping in papillary thyroid carcinoma is a fea-
sible technique with high accuracy for the detection of 
lymph node involvement. This technique can guide 
surgeons to perform central lymph node dissection only 
in patients with pathologically involved sentinel nodes. 
Although SLN detection in the lateral neck lymph 
nodes increases the extension of lymphadenectomy, 
SLN mapping can result in upstaging in older patients 
(> 45 years of age) or treatment plan change in younger 
patients (< 45 years of age) by the detection of lateral 
lymph node involvement. 
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